Incyte announced that its product Opzelura® (ruxolitinib) cream has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the treatment of moderate atopic dermatitis in adults.

老虎证券2026/06/26 11:42

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Semafor: Some members of Nvidia's board favor appointing CFO Colette Kress as interim CEO

BlockBeats•2026/11/12 02:33

Anthropic adapts its AI model to AMD GPU in just 3 days, challenging NVIDIA CUDA's competitive edge

格隆汇•2026/11/12 02:27

The 160 Threshold Under Threat Again! Yen Nears "Intervention Red Line," Tokyo May Spend Money Again to Rescue the Currency

The Japanese yen is approaching the 1 USD = 160 JPY level. Atsushi Mimura commented that the movement is "too fast." The US-Japan interest rate gap may widen further, and Japanese officials have hinted at being ready to intervene again.

智通财经•2026/11/12 02:26

Trimitra Trans Persada Secures Additional Rp 100 Billion Credit Facility From Bank Central Asia

Bitget•2026/11/12 01:44